Improved Mycobacterial Tetracycline Inducible Vectors

Reference number 7722, 7726, 7727, 7728

Sectors: Medical research, Pharmaceuticals

Industries: Medical research, Pharmaceuticals

Proposed use

Conditional gene expression systems are powerful tools for studying essential genes in bacteria. Tetracycline and its analogues are ideal inducer molecules as they regulate gene expression at very low concentrations (nM range), show good bio-availability (ie. they can penetrate both mycobacterial and animal cells), are non-toxic at the necessary levels and are stable over the required length of study.

Problem addressed

There is a lack of genetic tools available to researchers to study the function of essential mycobacterial genes, we have therefore constructed a range of improved tetracycline inducible vectors. We have shown that changing the terminators upstream of the inducible promoter does not affect background transcription, and that repressor binding to the operator is a more critical step in controlling regulation. We have eliminated further read-through problems by changing the backbone vector used. The TetRO promoter can be induced in a dose-dependent manner by tetracycline, anhydrotetracycline and doxycycline.

Technology overview

Plasmid Description
pMEND-Lx pMIND-Lx with Gly40 to Thr40 change in TetR
protein; episomal
pMEND-Lx-Int Integration version of pMEND-Lx
pKW08-Lx TetRO promoter from pMEND-Lx inserted into the
backbone of pSE100; episomal
pKW08-Lx-Int Integration version of pKW08-Lx

Additional information

These can be purchased for academic use directly through Addgene.


Williams KJ, Joyce G, Robertson BD. Improved mycobacterial tetracycline inducible vectors. Plasmid. 2010 Apr 29.

Inventor information

Dr Brian Robertson, Reader in Systems Microbiology, Department of Infectious Disease, Faculty of Medicine


Dr Brian Robertson

Reader in Systems Microbiology
Faculty of Medicine, Department of Infectious Disease

Visit personal site

Contact us about this technology


Dr Emily Allen-Benton

Industry Partnerships and Commercialisation Executive, Medicine

Emily is an IPC Executive within the Faculty of Medicine team focussed on intellectual property management, supporting Imperial academics with commercial engagement, fostering collaborative research and negotiating out-licenses. Emily manages an IP portfolio which included the Faculty of Medicine Quicktech portfolio, comprising mouse models and other research tools. Emily holds a PhD in Chemistry focussed on the sub-field of Synthetic Biology and has prior experience in the scientific publishing industry.

Contact Emily

[email protected]

Related technologies

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.